C-Terminal fragment of adiponectin receptor clinical correlations

The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre- diabetic assessment (n = 240). Patients with infl ammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies(n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10)were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) andimpaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and infl ammation. Patients using anti- TNF átherapies (Remicade® Infl iximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without signifi cant weight changes andthe within patient variability was 10 %. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 % sensitivity and 93 % specifi city. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive valuecriteria. Only 10 % of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.